{"name":"KaliVir Immunotherapeutics","slug":"kalivir-immunotherapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4AJBVV95cUxQeVZNVWFwdEFMaF9XX3ZiXzROaHZzaXdDRzF3azFneThSWFA4T3hzNzd1d2NiY0M5MXFTTW1ONlF2dk1XZUdDcTFtQ0YzXzJuOGtnQXp5U0h1ZnBIN0hURktsbmpaNUgyVTQtUzNLQVdxUk1ZUXhSV3o5YkFwYW5ISFg1WFVtSUtrSWszQmhTTVpwVG8wN3VfZ2ZsWUs4WkxrVGZHbkVUb1RtYm1kaThvNE11RGpmeEt1dklVN2NjQkFKc2duejJ0cGRwMVh4XzJsVWhLSzUzQWtoZmd4cENHVUVNa3RtT2lxQ1g5X0FqbmlxMVdBd3U4azgwb2c3QndTTW1LZ0pLd2NsbGFSenI4aG52dklkRG02LUFtenlyTGNQOXpqQVNiTV83eUZHVG4xbkhSaGtvbk9ITGtUYXR1eGpRVHQ4aVVTU0pfYkJRNUYtSXJpbGZuZ1ZpdTBaR1hZ?oc=5","date":"2025-11-19","type":"trial","source":"Business Wire","summary":"KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors - Business","headline":"KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI i","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxPNFhTN3VUb3M3b2JvYk5HcTl2N0M0dXJSTTJidkZHR2NHWWJDc284NjFlSUk2cndOM0V5cGR0NjB3TWlKRXZudkFUeUdROW5LazJzaW1RMjBMWkJsV09KS1c1WXdnbk9WQkdZOFdVM2xfR0ZyTEEtT3pjYjhZekJMNFhfZ05FYmRGMmxWSVQwUGJxVU1VQjRjdnY1aTBqOWd2bWRZdmpZNzlBdWtBR09HdWdFazBUTG41NkJqaDJFR3pQaWlHdHFWTTZPczFyeWM2eHlpSThsMHpfRy1wSnlwOXJJX2g0MW1WbXhiY0hTMDkyZUdudU1CamcyaHNydHI5RzRjZDNZOTNSZUN1eFg3aA?oc=5","date":"2025-05-20","type":"trial","source":"BioSpace","summary":"KaliVir Immunotherapeutics Announces Completion of First Cohort of STEALTH-001 Study Evaluating VET3-TGI in Patients with Advanced Solid Tumors - BioSpace","headline":"KaliVir Immunotherapeutics Announces Completion of First Cohort of STEALTH-001 Study Evaluating VET3-TGI in Patients wit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAJBVV95cUxQM1VHTzF4SUwwUmd3NVlnVGdxMTJoYWZBbFNNN3hnX3VVVVJUVm8tRjdYbGkwSm1tWmF1cmE0NkRwdFFpVTlQeC1GS0JvSm9hOW5UZmtxN3VLRW9rbWNxdEJWQi1BcDRLbzVtOFZ5U3dRd2s0ZGxja3JYc2diVGhFQ2xzMmlnZHdzVElaTTNwYjVDcU9DMjNJdHVValdlUnpKQ0tsWDBXdFpUS1ZUR3l2MGgxR004QzR5SzE1eGxMUC1Jb0tjd3E1V3hXR1pEandUQ3d0LW9hVlUtemtCdzIwb1RBaDBlUXFyVTZvYWF6VWtUVXJaRjdvTFVBVGM4dU5WM3VJOG45TEs0eHNvbl9vaWxtTElZbjdqODVnNg?oc=5","date":"2024-11-18","type":"patent","source":"Business Wire","summary":"KaliVir Immunotherapeutics Strengthens Innovation Portfolio with Issuance of Three New U.S. Patents Covering Its VET™ Product Candidates - Business Wire","headline":"KaliVir Immunotherapeutics Strengthens Innovation Portfolio with Issuance of Three New U.S. Patents Covering Its VET™ Pr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPWmh2M01ZUC1ENmhmTkdUbXdFSVlPcGh6S0F4ODNrV0ZaRERZdmV1M3Zjc0Q2S2UxSTBhMTVpVW56dHNaUDQtdU9QM0o0clNoWWhtNUd4T1ZUV05qVkNHNm9ET3JRa3FjQU9yU3NIWXAxa2pPVXdtMW1ZYjgxYk1EdVI2SERJenBXNjdhSTk1UG1TaVlINmhyWHpkRQ?oc=5","date":"2024-10-25","type":"pipeline","source":"Medical Marketing and Media","summary":"Rx Rundown: Opella, Samsung Biologics, Dimension and more - Medical Marketing and Media","headline":"Rx Rundown: Opella, Samsung Biologics, Dimension and more","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOSm85VW9NQWl5ZDY4NkxJRDZOWmJSZ1NpNDUxSDNXbWx6WDlFV3ZTUHlpT3RYXzVObGNiOXp2N0ZEY3YyWVp4OHQ0TE03SFhteVBwd1pNUERkMUZFZXRSY3N2RlJ4bXo2aGI1S2hITndpcjltYjc3Z1llQWhCVFRNa250UTg?oc=5","date":"2024-10-09","type":"trial","source":"Clinical Trials Arena","summary":"KaliVir doses first subject in Phase I/Ib solid tumour treatment trial - Clinical Trials Arena","headline":"KaliVir doses first subject in Phase I/Ib solid tumour treatment trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNc3FqT3cwTl9ZQmpwZkFvMmNxSkdLUk5MMzRIN0dmZjRUN2ZYbU9rMUM4cHJ5MUJlOG5PdjBOWHZVLXNTX3A0S2RQTjg5dnVFQzVrNlctMkVYWTloSjNIUklBRjhoSnZhUW5NRUtDbzF5d3FoRVAzeE0zc0kwbHVPdmU2eVdHaVA0LWJEN2NIZ1IyMGRZRG83T19LNHVGV2pZZDFKdFBSNnlWNnNSNV9rOUh2S3h4UHpMck5TMTVnbGpVTnBaZ3kzMm1oOExsMFpTV1dUUE43WThCbktheE95SmtlY1F4NmVPb3c?oc=5","date":"2024-10-08","type":"trial","source":"BioSpace","summary":"KaliVir Immunotherapeutics Doses First Patient in Phase 1/1b Trial of VET3-TGI for Incurable, Advanced, Solid Tumors - BioSpace","headline":"KaliVir Immunotherapeutics Doses First Patient in Phase 1/1b Trial of VET3-TGI for Incurable, Advanced, Solid Tumors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNNzc0ZWJfdXB5anpGQmxfc2FYd3hPNWFzU2lIdEE4N3J3UE9qbExPQ1VsUUxQRDdreGZHZmhmWG1KVlZxLVBIclFGRl9NcGFVTVMzaXQ0aFBwdmkyNEtQMHJuUzRpZzg4aWN4WlBkXzFKeWlUWW1QNlZfY1JhckZuelhBLVZJbDdydVJ0TlRaTUNOXzY4Wi1kbV9zelVLTmVORmhITEZySFpmR1NBdkRhYU5WYm0zclVa?oc=5","date":"2024-09-04","type":"pipeline","source":"citybiz","summary":"KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer - citybiz","headline":"KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}